Medical Condition News

RSS

FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

10 Aug 2011

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

10 Aug 2011

Patients receive inadequate medical monitoring for prescribed drugs in psychiatric settings

New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications that are common in patients with mental ill health - especially those prescribed antipsychotic medication.

10 Aug 2011

NCI, Genesis Biopharma sign CRADA agreement to develop cancer immunotherapies

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

10 Aug 2011

People more likely to use bowel screen test kit with GP letter

A letter of endorsement from their local doctor as well as a 'how-to-do-it' leaflet makes more people take part in bowel screening home tests - says a new study published in the British Journal of Cancer, today.

10 Aug 2011

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approvals for its prostate cancer FISH detection kit and Topoisomerase 2-alpha FISH detection kit from the State Food and Drug Administration of the People's Republic of China.

10 Aug 2011

Israeli OCS approves $1.7M grant to support PROLOR's hGH-CTP program

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.

10 Aug 2011

Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.

10 Aug 2011

Study suggests ways to remediate cognitive errors

Concern about the capacity of individuals with schizophrenia to consent to clinical research studies has largely focused on impairment due to psychotic symptoms associated with the disorder. Less attention has been given to the cognitive errors that prospective participants make when undergoing a formal assessment of decisional capacity.

10 Aug 2011

TrovaGene regains ownership of worldwide rights to transrenal technology

TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.

10 Aug 2011

Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders

Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.

10 Aug 2011

Acorda Therapeutics receives U.S. patent allowance for aminopyridine compositions

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled "Method of Using Sustained Release Aminopyridine Compositions."

10 Aug 2011

Nesfatin-1 protein may help reduce body weight and blood sugar

A newly-identified protein may hold the key to keeping appetite and blood sugar in check, according to a study by York University researchers.

10 Aug 2011

Scientist determines how nyctalopin gene makes night vision possible

A scientist from the Florida campus of The Scripps Research Institute has determined how a particular gene makes night vision possible. The study, which was published in the August 10, 2011 edition of The Journal of Neuroscience, focuses on a gene called nyctalopin. Mutations in the gene result in inherited "night blindness," a loss of vision in low-light environments.

10 Aug 2011

Elderly women with sleep apnea more likely to develop dementia

Elderly women who suffer from sleep apnea -- characterized by disrupted breathing and sleep and a reduction in the intake of oxygen -- are about twice as likely to develop dementia in the next five years as those without the condition, according to a multi-center study led by researchers from the University of California, San Francisco.

10 Aug 2011

New technique can help scientists rapidly map myelination

Like explorers mapping a new planet, scientists probing the brain need every type of landmark they can get. Each mountain, river or forest helps scientists find their way through the intricacies of the human brain.

10 Aug 2011

Moberg Derma receives first order for Emtrix from Walmart

The public company Moberg Derma AB has through its U.S. distributor Alterna LLC received a first order from the world's largest retail chain, Walmart, for Emtrix - its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

10 Aug 2011

NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers

Pharmacyclics, Inc. today announced the signing of a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765, a first-in-class, small molecule inhibitor of Bruton's tyrosine kinase (Btk) for the treatment of hematologic malignancies.

10 Aug 2011

IntraPace connect.abiliti Wand H102 system receives European CE Mark

IntraPace, Inc. announced today that it has received European CE Mark for the connect.abiliti Wand H102. The device provides wireless access to personal eating and exercise data to patients with an abiliti system, a unique approach to the treatment of obesity that uses gastric stimulation to help patients feel full sooner.

10 Aug 2011

Transaxillary thyroid robotic surgery removes nodules with no visible scar

As the rate of thyroid cancer continues to climb, doctors are urging patients to be more cautious about thyroid nodules, a common disorder that is responsible for a small but growing number of thyroid cancer cases.

10 Aug 2011